10.3389/fimmu.2019.00865.s001
Alessandro Mangogna
Alessandro
Mangogna
Chiara Agostinis
Chiara
Agostinis
Deborah Bonazza
Deborah
Bonazza
Beatrice Belmonte
Beatrice
Belmonte
Paola Zacchi
Paola
Zacchi
Gabriella Zito
Gabriella
Zito
Andrea Romano
Andrea
Romano
Fabrizio Zanconati
Fabrizio
Zanconati
Giuseppe Ricci
Giuseppe
Ricci
Uday Kishore
Uday
Kishore
Roberta Bulla
Roberta
Bulla
Table_1_Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas.DOCX
Frontiers
2019
complement
classical pathway
C1q
tumor
microenvironment
prognosis
2019-05-03 04:10:41
Dataset
https://frontiersin.figshare.com/articles/dataset/Table_1_Is_the_Complement_Protein_C1q_a_Pro-_or_Anti-tumorigenic_Factor_Bioinformatics_Analysis_Involving_Human_Carcinomas_DOCX/8073929
<p>C1q is the first subcomponent of the classical pathway of the complement system and belongs to the C1q/Tumor Necrosis Factor superfamily. C1q can perform a diverse range of immune and non-immune functions in a complement-dependent as well as -independent manner. Being a pattern recognition molecule of the innate immunity, C1q can recognize a number of self, non-self and altered-self ligands and bring about effector mechanisms designed to clear pathogens via opsonisation and inflammatory response. C1q is locally synthesized by macrophages and dendritic cells, and thus, can get involved in a range of biological processes, such as angiogenesis and tissue remodeling, immune modulation, and immunologic tolerance. The notion of C1q involvement in the pathogenesis of cancer is still evolving. C1q appears to have a dual role in cancer: tumor promoting as well as tumor-protective, depending on the context of the disease. In the current study, we performed a bioinformatics analysis to investigate whether C1q can serve as a potential prognostic marker for human carcinoma. We used the Oncomine database and the survival analysis platforms Kaplan-Meier plotter. Our results showed that high levels of C1q have a favorable prognostic index in basal-like breast cancer for disease-free survival, and in HER2-positive breast cancer for overall survival, while it showed a pro-tumorigenic role of C1q in lung adenocarcinoma, and in clear cell renal cell carcinoma. This in silico study, if validated via a retrospective study, can be a step forward in establishing C1q as a new tool as a prognostic biomarker for various carcinoma.</p>